Foral Pamela A, Nystrom Kelly K, Wilson Amy F, Christensen Carla M
Alegent Health Bergan Mercy Medical Center, Omaha; Creighton University, Omaha, Nebraska 68178, USA.
Drugs Today (Barc). 2003 Dec;39(12):939-48. doi: 10.1358/dot.2003.39.12.799412.
Selective cyclooxygenase-2 (COX-2) inhibitors are used for the treatment of inflammation and pain while having the reported advantage of fewer upper gastrointestinal adverse effects compared to traditional nonsteroidal anti-inflammatory drugs. Although fewer adverse effects occur, there is still a risk for developing upper gastrointestinal adverse effects. Clinical practitioners have increased concern regarding this risk. The belief that COX-2 inhibitors are safe for the gastrointestinal tract has been questioned. This has encouraged the proposal of several explanations on the mechanism of gastromucosal injury and healing relative to COX isoenzymes. These mechanisms are delineated in the following review, along with the gastrointestinal safety, risk factors, clinical and case studies, and cost effectiveness of the COX-2 inhibitors.
选择性环氧化酶-2(COX-2)抑制剂用于治疗炎症和疼痛,与传统非甾体抗炎药相比,具有上消化道不良反应较少的优势。尽管不良反应较少,但仍有发生上消化道不良反应的风险。临床医生对这种风险的关注度有所增加。COX-2抑制剂对胃肠道安全的观点受到了质疑。这促使人们提出了几种关于胃黏膜损伤和愈合与COX同工酶相关机制的解释。以下综述将阐述这些机制,以及COX-2抑制剂的胃肠道安全性、危险因素、临床和案例研究,还有成本效益。